SAQ 1 — Classification, prevalence and the bedside safety conversation

Stem (20 marks; suggested 15 minutes): [1]

A four-year-old child of South Asian heritage presents with three weeks of abdominal pain, constipation and lethargy. The blood count shows a microcytic anaemia. On direct, non-judgemental questioning, the mother reveals the child has been taking an Ayurvedic preparation "for strength" for two months. Separately, the mother of a 10-year-old with epilepsy asks whether the St John's wort she has started giving him "for mood" is safe alongside his antiseizure medicines. [8] [5]

(a) Define complementary and alternative medicine (CAM), name the five CAM domains, and classify the two products above into the most relevant domain. (8 marks) [1]

(b) Outline the stepwise bedside safety conversation you would have with each family, and state why routine, non-judgemental asking is the single most important intervention. (8 marks) [4]

(c) For the first child, state the most likely diagnosis, the first-line investigation, and one immediate management step. (4 marks) [6]

Model answer — SAQ 1

(a) Definition, five domains and classification (8 marks). [1]

• Definition — CAM is a diverse group of health systems, practices and products not presently considered part of conventional biomedicine: complementary when used alongside conventional care, alternative when used instead of it, integrative when evidence-based CAM is combined with conventional care in a coordinated way. (2 marks)
• Five domains — (1) biologically based therapies (herbs, botanicals, vitamins, supplements); (2) mind-body medicine (meditation, yoga, hypnosis); (3) manipulative and body-based practices (massage, chiropractic, osteopathy); (4) energy therapies (Reiki, biofield); (5) whole medical systems (Ayurveda, traditional Chinese medicine, homeopathy, naturopathy, Indigenous healing). (5 marks)
• Classification — the Ayurvedic preparation is a whole medical system product (Ayurveda) and is the principal source of heavy-metal contamination; the St John's wort is a biologically based therapy (botanical) and is the principal source of herb-drug interactions. (1 mark) [1] [7]

(b) Bedside safety conversation (8 marks — the six steps, 1 mark each, capped at 8). [4]

1. Ask respectfully and routinely — use open, normalised wording ("Lots of families give their children herbs, vitamins or traditional remedies — does your child take any?") rather than closed or judgemental questions. [4]
2. Document every remedy — name, dose, frequency, route, source and recommender, in the same place as conventional medicines. [4]
3. Screen for interactions and contamination — for the St John's wort, check against the antiseizure medicines for CYP3A4 interactions; for the Ayurvedic preparation, consider heavy-metal contamination. [5]
4. Assess the evidence and the risk — is it directly harmful; is it substituting for proven care; is the child particularly vulnerable? [4]
5. Counsel honestly and collaboratively — explain the assessment in plain language, respect the family's beliefs, use shared decision-making; do not dismiss CAM wholesale. [4]
6. Coordinate and follow up — integrate agreed safe CAM, arrange follow-up, report adverse events. [4]

Routine, non-judgemental asking is the single most important intervention because non-disclosure is the default — a parent who fears disapproval will not volunteer CAM use, so the only way to surface the hidden pathways is to ask openly and routinely. (credit within step 1) [1]

(c) Diagnosis, investigation and immediate management (4 marks). [6]

• Most likely diagnosis — lead poisoning from a contaminated Ayurvedic preparation; the abdominal pain, constipation, lethargy and microcytic anaemia are the classic paediatric presentation. (1 mark) [8]
• First-line investigation — a venous blood lead level (with arsenic and mercury levels if the exposure history suggests them); basophilic stippling on the blood film supports the diagnosis. (2 marks) [6]
• Immediate management step — stop the Ayurvedic product and involve the toxicology service (chelation is guided by the blood level and specialist advice; supportive care is the backbone). Arrange for the product to be tested and notify public health. (1 mark) [8]

SAQ 2 — Herb-drug interactions, homeopathy and the regulatory picture

Stem (20 marks; suggested 15 minutes): [5]

A fellowship examiner asks: "Why does complementary and alternative medicine sometimes harm children, and how should clinicians and regulators respond?" [1] [4]

(a) Describe the four pathways by which CAM use harms children, giving a named example of each. (10 marks) [7]

(b) Summarise the evidence on homeopathic products for children, and describe the regulatory frameworks in the WHO, UK, Australia and the United States. (10 marks) [10]

Model answer — SAQ 2

(a) Four pathways to harm (10 marks — 2.5 marks per pathway: name, mechanism, named example). [7]

• Adulteration and heavy-metal contamination — Ayurvedic bhasmas, traditional Chinese medicines and imported remedies may contain lead, arsenic or mercury. Named example: the child in SAQ 1 with lead poisoning from an Ayurvedic preparation (Datta-Mitra 2015; Ernst 2002; McRae 2024). [7] [8]
• Herb-drug interactions via cytochrome P450 and P-glycoprotein — St John's wort induces CYP3A4 and P-glycoprotein, lowering ciclosporin, tacrolimus, warfarin, oral contraceptives, anticonvulsants and HIV protease inhibitors. Named example: a transplant child whose ciclosporin level falls and graft rejects after St John's wort is started (Feucht and Patel 2011). [5]
• Misidentification and dosing inconsistency — biological products vary by batch and species; the wrong species is toxic. Named example: star-anise tea contaminated with the neurotoxic Japanese star anise (Illicium anisatum) causing seizures in infants given the tea for colic. [5]
• Delay or displacement of conventional care — the most serious harm is substituting an unproven CAM product for proven treatment. Named example: a family stopping a child's chemotherapy or anticonvulsant in favour of an alternative remedy — a safeguarding as well as a pharmacology problem (Gilmour 2011). [4]

(b) Homeopathy evidence and regulatory frameworks (10 marks). [10]

• Homeopathy evidence — the 2022 Cochrane review (Hawke et al.) found no evidence that homeopathic products prevent or treat acute respiratory tract infections in children; homeopathic products must not replace proven treatment, oral rehydration, antibiotics or immunisation. The historical concern about belladonna-containing homeopathic teething products, linked to seizures in infants and regulatory warnings, is the specific paediatric safety example. (2 marks) [10]
• WHO — the WHO Traditional Medicine Strategy (2014-2023, extended) promotes safe, effective and quality traditional and complementary medicine through national policy, regulation, research and informed consumer choice — integration, not prohibition. (2 marks) [1]
• UK — the MHRA regulates registered herbal medicines with a Traditional Herbal Registration mark for quality and safety; unregistered and compounded products are where contamination enters; the Yellow Card scheme has a dedicated CAM section for adverse-event reporting. (2 marks) [7]
• Australia and Aotearoa New Zealand — the TGA regulates listed (AUST L, quality and safety but not efficacy) and registered complementary medicines; the RCH Melbourne guidelines are a practical reference; adverse events are reported through the Blue Card scheme; rongoā Māori is recognised within culturally safe care. (2 marks) [7]
• United States — dietary supplements are regulated under DSHEA 1994, which treats supplements more like foods than drugs: manufacturers do not have to prove safety or efficacy before marketing, and the burden falls on the FDA to demonstrate harm. This lighter regime is the structural reason contamination and inconsistent dosing persist. Adverse events are reported through MedWatch. (2 marks) [8]